☆ 4.6 Article

Clustering using unsupervised machine learning to stratify the risk of immune-related liver injury

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Takafumi Yamamoto et al.

Summary: Liver immune-related adverse events (liver-irAEs) were observed in 42.7% of NSCLC patients treated with ICIs, with a median onset time of 53 days postinjection. Patients with liver-irAEs had significantly worse survival outcomes compared to those without liver-irAEs.

CANCER INVESTIGATION (2022)

添加到收藏夹

Article Oncology

Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma

Marcus Woelffer et al.

Summary: The aim of this study was to investigate the associations between clinical parameters or NGS-based genetic alterations and the occurrence of immune-related adverse events (IRAE) in melanoma patients with immune checkpoint inhibitors (ICI). The results showed that female sex was significantly associated with the development of hepatitis, increased monocytes at therapy initiation were significantly associated with the development of pancreatitis, and several genetic alterations were identified as being associated with IRAE. These findings can help assess the risk of IRAE in melanoma patients with ICI, but larger studies are needed to confirm the results.

CANCERS (2022)

添加到收藏夹

Article Urology & Nephrology

Clustering phosphate and iron-related markers and prognosis in dialysis patients

Hikaru Morooka et al.

Summary: This study investigated the prognosis of dialysis patients by clustering them based on phosphate, hemoglobin, and iron-related markers. The use of phosphate binders was found to be associated with lower risk of all-cause death in two clusters, highlighting the potential benefits of oral phosphate binder therapy in certain patient populations.

CLINICAL KIDNEY JOURNAL (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients

Maaike Biewenga et al.

Summary: The incidence of checkpoint inhibitor-induced hepatitis was found to be 1.8% for PD-1 inhibitor, 2.6% for ipilimumab, and 20.7% for combination therapy in a real-world cohort. However, the hepatitis did not have any relation with liver metastasis and did not negatively impact the outcome.

HEPATOLOGY INTERNATIONAL (2021)

添加到收藏夹

Review Oncology

Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-A Comprehensive Review

Josefien W. Hommes et al.

Summary: ICIs have improved cancer patient prognosis by blocking negative feedback mechanisms of the immune system, but can also lead to auto-immune toxicities. Despite numerous studies, no single biomarker has yet been proven to sufficiently predict the development of irAEs.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis

Donghui Wang et al.

Summary: The meta-analysis showed that immune-related adverse events (irAEs) were associated with the efficacy of immune checkpoint inhibitors in lung cancer patients, with dermatological, endocrine, and gastrointestinal irAEs being predictors of enhanced efficacy.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors

Despina Michailidou et al.

Summary: This study investigated the association between immune related adverse events (irAEs) and biomarkers in cancer patients receiving immune checkpoint inhibitors, identifying several risk factors. Patients with specific laboratory markers and clinical features had an increased risk of irAEs while lower NLR, MLR, and PLR were associated with longer overall survival. These findings suggest that baseline measurements and autoimmune history play a role in predicting irAEs and outcomes.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies

Takanori Ito et al.

Summary: The occurrence pattern and therapeutic response to corticosteroids in immune-related liver injury differ according to the injury type, with corticosteroids effective for the hepatocellular pattern but not for refractory non-hepatocellular patterns, indicating the need for additional strategies in such cases.

HEPATOLOGY INTERNATIONAL (2021)

添加到收藏夹

Article Critical Care Medicine

Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain

Alejandro Rodriguez et al.

Summary: The study identified three clinical phenotypes that significantly correlated with host-response patterns and ICU mortality using a machine learning model, showing different risk factors across the whole population and clinical phenotypes, which may limit the application of a one-size-fits-all model in practice.

CRITICAL CARE (2021)

添加到收藏夹

Article Oncology

Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study

Saeka Egami et al.

Summary: This study aimed to investigate the association between immune-related adverse events (irAEs) and peripheral blood cell counts in patients receiving pembrolizumab for advanced non-small cell lung cancer (NSCLC). The results showed that patients with higher pretreatment absolute lymphocyte count (ALC) and lymphocyte-to-monocyte ratio (LMR) had a reduced risk of developing any irAEs, while patients with higher pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) had an increased risk. Routine evaluation of blood cell count data before pembrolizumab treatment initiation may help identify early-onset irAEs during the first 6 weeks of treatment.

JOURNAL OF CANCER (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies

Kazuyuki Mizuno et al.

JOURNAL OF GASTROENTEROLOGY (2020)

添加到收藏夹

Article Oncology

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

Lihong Peng et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation

Thoetchai (Bee) Peeraphatdit et al.

HEPATOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan

Takashi Kitagataya et al.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy

Keisuke Yokohama et al.

SCIENTIFIC REPORTS (2020)

添加到收藏夹

Article Critical Care Medicine

Cognitive phenotypes 1 month after ICU discharge in mechanically ventilated patients: a prospective observational cohort study

Sol Fernandez-Gonzalo et al.

CRITICAL CARE (2020)

添加到收藏夹

Article Medicine, General & Internal

Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis

Christopher W. Seymour et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

添加到收藏夹

Review Immunology

Development of immune checkpoint therapy for cancer

Jill M. Fritz et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2019)

添加到收藏夹

Review Oncology

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Filipe Martins et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors

Alberto Pavana et al.

ONCOLOGIST (2019)

添加到收藏夹

Article Oncology

C-reactive protein as an early marker of immune-related adverse events

Amir-Reza Abolhassani et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Critical Care Medicine

ICU staffing feature phenotypes and their relationship with patients' outcomes: an unsupervised machine learning analysis

Fernando G. Zampieri et al.

INTENSIVE CARE MEDICINE (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab

Yeonghee Eun et al.

SCIENTIFIC REPORTS (2019)

添加到收藏夹

Review Oncology

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

Satya Das et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Oncology

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

Eleonora De Martin et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Article Medicine, Research & Experimental

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade

Sara Valpione et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2018)

添加到收藏夹

Review Medicine, General & Internal

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Michael A. Postow et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis

Danielle Benedict Sacdalan et al.

ONCOTARGETS AND THERAPY (2018)

添加到收藏夹

Review Oncology

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis

Daniel Y. Wang et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data

Wenjun Wang et al.

INTERNATIONAL JOURNAL OF CANCER (2017)

添加到收藏夹

Article Oncology

Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors

Adam Diehl et al.

ONCOTARGET (2017)

添加到收藏夹

Review Hematology

Current concepts in the diagnosis and management of cytokine release syndrome

Daniel W. Lee et al.

BLOOD (2014)

添加到收藏夹

Article Biophysics

Investigation of the freely available easy-to-use software 'EZR' for medical statistics

Y. Kanda

BONE MARROW TRANSPLANTATION (2013)

添加到收藏夹

Article Medicine, General & Internal

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.